Cistron Biotechnology(CIST)$.30 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (1648)	11/9/1998 9:16:00 PM
From: Rudy Saucillo	Read Replies (1) of 2742

I think the near term potential for CIST is the possibility that Naismith will cut a deal to sell all or part of Cistron. I don't believe we'll see any new adjuvant data from Cistron or PMC for another year or so. And I don't believe Cistron's wound healing data is strong enough yet for another partnership. There's absolutely no excuse for Cistron not being able to duplicate existing research in cancer vaccine adjuvants. Their data in this area was pathetic, and assuming that cancer was not included in the PMC agreement (although I think it is), Cistron's current data certainly won't attract a new partnership in this area. I believe, given Cistron's cash and patent position, that there's still a real possibility for a sale of assets. Rudy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next